

August 27, 2025

RE: **Updates in Advanced Breast Cancer: Local Management and Other New Perspectives**  
Marriott Medical Center Hotel Houston  
6580 Fannin Street  
Houston, TX 77030

Dear Potential Exhibitor:

On behalf of **The University of Texas MD Anderson Cancer Center** and **Activity Director, Bora Lim, MD**, Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine and **Co-Director, Chunru Lin, PhD**, Associate Professor, Department of Molecular and Cellular Oncology, Division of Basic Science Research we would like to invite you to exhibit at our upcoming **Updates in Advanced Breast Cancer: Local Management and Other New Perspectives**, scheduled for **February 27 – 28, 2026** at the **Marriott Medical Center Hotel Houston** in **Houston, Texas**. We offer a variety of exhibitor packages, as well as some Non-CE Satellite Symposium opportunities for your consideration, each designed to provide unique opportunities for participation.

## OVERVIEW

This activity emphasizes the integration of novel therapies and diagnostic tools into clinical practice, including liquid biopsy, ctDNA, and MRD monitoring for inflammatory breast cancer (IBC). It also explores DDR-targeted strategies, CAR-T therapy limitations, and the role of T-cell receptor and vaccine-based immunotherapies. Experts will highlight interdisciplinary collaboration, including the roles of nurse navigators, advanced practice providers, and social workers.

## NEEDS ASSESSMENT

The rapidly evolving and increasingly intricate landscape of oncology care necessitates continual advancement in clinical knowledge, diagnostic integration, and therapeutic management. Clinicians are under mounting pressure to keep pace with a deluge of emerging, guideline-driven treatments while also incorporating sophisticated diagnostic modalities—such as circulating tumor DNA (ctDNA) and measurable residual disease (MRD) assays—into routine practice. At the same time, the introduction of novel therapies has led to complex and often unpredictable toxicity profiles, exposing significant gaps in the early recognition and effective management of treatment-related adverse events. These clinical challenges are compounded by enduring systemic, financial, and social barriers that obstruct access to high-quality cancer care, disproportionately burdening underserved populations. This activity is designed to bridge these gaps by empowering multidisciplinary oncology teams with the most current, evidence-based knowledge; actionable strategies for managing toxicities; and practical tools to deliver equitable, patient-centered care in a complex and rapidly changing therapeutic environment.

## KNOWLEDGE GAP

Despite the proliferation of innovative cancer therapies, significant and urgent knowledge gaps persist among healthcare professionals regarding the mechanisms of action, clinical applications, and inherent limitations of DNA damage response (DDR)-targeted therapies, chimeric antigen receptor T-cell (CAR-T) therapies, and next-generation immunotherapeutic modalities such as T-cell receptor (TCR)-engineered and vaccine-based strategies. Many clinicians report uncertainty or lack of familiarity with appropriate patient selection, optimal sequencing, and precise interpretation of response or resistance, as well as management of unique and potentially severe adverse effects. These deficiencies are compounded by a critical need for better understanding of the complex biologic, genetic, and environmental factors influencing breast cancer risk and progression—particularly in younger and historically underserved populations. This includes integrating recent data on the implications of GLP-1 receptor agonists and modifiable environmental exposures, both of which may profoundly affect

long-term outcomes. Without targeted educational interventions to address these intersecting gaps, the promise of truly personalized and equitable cancer care remains out of reach. Bridging these gaps is essential to empower clinicians with the tools needed for evidence-based, patient-centered decision-making and to accelerate the advancement of precision oncology across all patient populations.

### COMPETENCE GAP

Clinicians require enhanced competence in the interpretation and application of circulating tumor DNA (ctDNA) and measurable residual disease (MRD) data to inform evidence-based management of invasive breast cancer (IBC). In addition to technical proficiency, there is a critical need to strengthen interdisciplinary collaboration and care coordination—including optimizing communication and workflow with advanced practice providers (APPs), nurse navigators, and social workers—to ensure seamless, patient-centered oncology care. Addressing these gaps is essential for translating complex molecular data into actionable clinical strategies and for supporting optimal outcomes across the continuum of care.

This activity aims to revolutionize personalized treatment in advanced breast cancer, enhancing healthcare professionals' competence and performance. The goal is improved patient outcomes through updated, evidence-based practices.

### OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Evaluate and apply DDR-targeted and CAR-T strategies in the treatment of advanced breast cancer.
- Incorporate ctDNA and MRD monitoring into clinical decision-making for advanced breast cancer patients.
- Identify and manage emerging toxicities associated with novel therapies in advanced breast cancer care.
- Integrate immunotherapy and vaccine-based approaches into treatment plans for oligometastatic and inflammatory breast cancer.
- Enhance interdisciplinary collaboration, including the roles of social workers, advanced practice providers, and nurse navigators to improve patient outcomes.

### TARGET AUDIENCE

We are anticipating 125 Physicians, Nurse Practitioners, Physician Associates, Nurses, Pharmacists, Social Workers, Genetic Counselors, Students and Trainees.

### EXHIBIT OPPORTUNITIES

---

#### PLATINUM – \$10,000

- Five Complimentary Registrations
- Five complimentary reception tickets – Friday, February 27, 2026, at 5:00 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website, and the ability to post 3 – 6 product information (pdfs)
- Designated premium location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Platinum level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

#### GOLD – \$7,500

- Four Complimentary Registrations
- Four complimentary reception tickets – Friday, February 27, 2026, at 5:00 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website
- Designated premium location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Gold level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### SILVER – \$5,000

- Three Complimentary Registrations
- Three complimentary reception tickets – Friday, February 27, 2026, at 5:00 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name and link to company website
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Silver level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### BRONZE – \$2,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Friday, February 27, 2026, at 5:00 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### NON-PROFIT – \$1,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Friday, February 27, 2026, at 5:00 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

## ADDITIONAL WAY TO PARTICIPATE

*Please note you must be participating as an exhibitor to qualify for the following option.*

---

### Non-CE Satellite Symposium – \$15,000

A 45-minute informational presentation and discussion by industry representatives and others speaking on behalf of their company offers healthcare providers with valuable scientific and clinical information about medicines that may lead to improved patient care. Satellite Symposiums provide the platform for these valuable presentations. Please review the following for important information. If your company is interested, you may choose from the following option(s).

<b>Friday, February 27, 2026</b> 2 Opportunities Available	<b>Time:</b> 7:00 – 8:15 am
---	-----------------------------

### Presentation Information

Satellite Symposium are promotional presentations that highlight a new service or provide material about product development. A Satellite Symposium should be appropriate and professional, as well as focus on the science related to the development of product or of a service provide by the company.

Satellite Symposium sponsors are not permitted to certify the Satellite Symposium by a CE Provider and must submit faculty and topics to CPE for approval.

Submit the following information by January 30, 2026, to [rpdavis@mdanderson.org](mailto:rpdavis@mdanderson.org)

- Title of Presentation for the Satellite Symposium Presentation
- Name, Title, Credentials and contact information of the speaker/faculty
- Two bullet points that provide a description of the Satellite Symposium topic

A Satellite Symposium sponsor is responsible for the content of its presentation, including obtaining all appropriate copyright permissions and licenses for slides and other materials that will be presented or distributed.

#### **Satellite Symposiums Accepted**

A completed agreement, with full payment are accepted for Satellite Symposiums on a first-come, first-served basis.

#### **Non-CE Satellite Symposium, Requirements**

1. Participation as a confirmed exhibitor.
2. Submission of a completed agreement accompanied by full payment.
3. Assignment on a first-come, first-served basis.

#### **CONFERENCE LOCATION**

##### **Marriott Medical Center Hotel Houston**

6580 Fannin Street  
Houston, TX 77030

#### **CONFERENCE TIMES**

<b>Friday, February 27, 2026</b>	<b>Saturday, February 28, 2026</b>
Conference: 8:20 – 5:00 AM	Conference: 8:20 AM – 12:00 PM
Set-Up: 6:30 – 7:30 AM	Set-Up: 7:00 – 7:30 AM
Check-in/Breakfast: 7:30 AM	Check-in/Breakfast: 7:30 AM
Dismantle: 5:00 PM	Dismantle: 10:20 AM

#### **REGISTER**

[Please Click Here for More Information or To Register.](#)

To register as an exhibitor, click on the Exhibitor tab, select Exhibit at this Event

Please note: Registration and an exhibit agreement are necessary to participate as an exhibitor. The exhibit is not considered confirmed until your company has registered, and we have a fully executed agreement. The agreement and payment should be received prior to the activity.


Please let me know if you have any questions or need any additional information for this request. We appreciate your consideration to participate as an exhibitor at this exceptional educational activity.

I look forward to hearing from you soon.


Best,

**Robyn P. Davis**

Senior Continuing Education Coordinator  
Continuing Professional Education  
The University of Texas MD Anderson Cancer Center



Day 1 – February 27, 2026	
7:30 AM	Check-In / Breakfast
8:20 AM	<b>Welcome and Conference Goals</b>
<b>Session 1: Keynote</b>	Introduction
8:30 – 9:20 AM	<b>Updates in DDR targeted strategy in breast cancer</b>
<b>Session 2: Brain and Liver Metastasis</b>	
9:20 – 9:40 AM	<b>New strategy to overcome the CAR-T barrier in current breast cancer therapy</b>
9:40 – 10:00 AM	<b>Imaging strategy to track the breast cancer therapy delivery</b>
10:00 – 10:20 AM	<b>Break and Exhibits</b>
10:20 – 10:40 AM	<b>Brain met targeted combination strategy</b>
10:40 – 11:00 AM	<b>The next step to revive the fitness of liver cells to fight off metastasis</b>
<b>Session 3: Patient Advocacy</b>	
11:00 – Noon	<b>Patient Panel Discussion:</b>
Noon – 1:00 PM	<b>Lunch with Advocates:</b> Panel Discussion ( <i>No CE Credit Awarded</i> ) Social Work <b>Professor's Corner</b>
<b>Session 4: Management of Toxicity in ABC Care</b>	
1:00 – 1:20 PM	<b>Interstitial Lung Disease</b>
1:20 – 1:40 PM	<b>Cardiac Complication and Immunotherapy Side Effects, New Way to Gather and Implement the Data</b>
1:40 – 2:00 PM	<b>New Toxicities of New Therapies</b>
2:00 PM	<b>Break and Exhibits</b>
<b>Session 5: environmental factor and immune modulation in breast cancer</b>	
2:20 – 2:40 PM	<b>B cells in breast cancer therapy resistance</b>
2:40 – 3:00 PM	Epidemiological factor of young breast cancer patients
3:00 – 3:20 PM	<b>GLP-1 agonist and breast cancer</b>
3:20 – 3:40 PM	<b>Panel Discussion</b> All Session Speakers
3:40 – 4:00 PM	<b>Break and Exhibits</b>
<b>Session 6: Optimizing multi-disciplinary care</b>	
4:00 – 4:20 PM	<b>Financial support/grant program of ABC care</b>



4:20 – 4:40 PM	<b>The role of mid-level in the ABC care</b>
4:40 – 5:00 PM	<b>Nurse navigation of ABC patients</b>
5:00 PM	Welcome Reception <i>All Participants, Faculty, Advocates and Exhibitors included</i>

Day 2 – February 28, 2026	
7:30 AM	Check-In / Breakfast
8:20 AM	<b>Welcome and Conference Goals</b>
<b>Session 7: Keynote II</b> Introduction	
8:30 – 9:00 AM	<b>How to utilize T cell receptor information in breast cancer</b>
9:00 – 9:20 AM	<b>Break and Exhibits</b>
<b>Session 8: How to make the best immunotherapy approach</b>	
9:20 – 9:40 AM	<b>Immunopeptidome to Vaccine: strategy in the IBC</b>
9:40 – 10:00 AM	<b>New way of cancer vaccine: how to utilize RT to induce immune response, and how to tackle oligometastatic breast cancer</b>
10:00 – 10:20 AM	<b>Break and Exhibits</b>
10:20 – 10:40 AM	<b>Overlap between TNBC vs IBC focused on microenvironment</b>
10:40 – 11:00 AM	<b>Panel Discussion</b>
<b>Session 9: Best way to integrate the liquid biopsy in current ABC care</b>	
11:00 – 11:20 AM	<b>IBC clear and de-centralized approach in collecting/analyzing ctDNA</b>
11:20 – 11:40 AM	<b>Can the MRD be cleared by systemic intervention?</b>
11:40 AM – Noon	<b>Updated data on neoadjuvant monitoring of IBC ctDNA</b>
Noon	Adjournment

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type.  
See Specific Instructions on page 3.

1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.)  
**The University of Texas MD Anderson Cancer Center**

2 Business name/disregarded entity name, if different from above.

3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only **one** of the following seven boxes.  

☐ Individual/sole proprietor    ☐ C corporation    ☐ S corporation    ☐ Partnership    ☐ Trust/estate

☐ LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) \_\_\_\_\_  
**Note:** Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.

☒ Other (see instructions)    **Agency within the Government of the State of Texas**

3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions ☐

4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):  
Exempt payee code (if any)    **3**  
Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any)    **C**  
*(Applies to accounts maintained outside the United States.)*

5 Address (number, street, and apt. or suite no.). See instructions.  
**1515 Holcombe Boulevard**

6 City, state, and ZIP code  
**Houston, TX 77030**

7 List account number(s) here (optional)

Requester's name and address (optional)

**Part I Taxpayer Identification Number (TIN)**  
Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.  
**Note:** If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number  

-

-

or  
Employer identification number  

7

4

-

6

0

0

1

1

1

8

**Part II Certification**  
Under penalties of perjury, I certify that:  
1. The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and  
2. I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and  
3. I am a U.S. citizen or other U.S. person (defined below); and  
4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.  
**Certification instructions.** You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here  
Signature of U.S. person    **Omer F. Sultan**  
Date    **2/11/2025 | 9:47 AM CST**

**General Instructions**  
Section references are to the Internal Revenue Code unless otherwise noted.  
**Future developments.** For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9).  
**What's New**  
Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

**Purpose of Form**  
An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they

Cat. No. 10231X

Form **W-9** (Rev. 3-2024)